AC Immune SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACIU Nasdaq 8731 https://www.acimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AC Immune SA

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Mar 20th, 2023 12:00 pm
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update - Mar 16th, 2023 11:00 am
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 - Mar 8th, 2023 12:00 pm
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 - Feb 7th, 2023 12:00 pm
AC Immune to Present at the SVB Securities Global Biopharma Conference - Feb 2nd, 2023 1:15 pm
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance - Jan 27th, 2023 2:57 pm
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial - Jan 26th, 2023 12:00 pm
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease - Jan 18th, 2023 12:00 pm
AC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29% - Jan 7th, 2023 1:45 pm
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development - Nov 30th, 2022 12:00 pm
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely? - Nov 25th, 2022 12:17 pm
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference - Nov 23rd, 2022 12:30 pm
AC Immune to Present at the Jefferies London Healthcare Conference - Nov 8th, 2022 12:58 pm
Shareholders in AC Immune (NASDAQ:ACIU) are in the red if they invested five years ago - Oct 29th, 2022 12:06 pm
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates - Oct 28th, 2022 1:25 pm
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Oct 28th, 2022 12:00 pm
AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome - Oct 4th, 2022 12:36 pm
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease - Sep 26th, 2022 11:30 am
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent - Sep 1st, 2022 12:00 pm
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases - Aug 24th, 2022 8:05 pm